REFERENCES
1. Interthal H, Pouliot JJ, Champoux JJ. The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. Proc Natl Acad Sci U S A 2001;98:12009-14.
2. Pouliot JJ, Yao KC, Robertson CA, Nash HA. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. Science 1999;286:552-5.
3. Yang SW, Burgin AB Jr, Huizenga BN, Robertson CA, Yao KC, et al. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc Natl Acad Sci U S A 1996;93:11534-9.
4. Comeaux EQ, van Waardenburg RC. Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target. Drug Metab Rev 2014;46:494-507.
5. Ben Hassine S, Arcangioli B. Tdp1 protects against oxidative DNA damage in non-dividing fission yeast. EMBO J 2009;28:632-40.
6. Das BB, Dexheimer TS, Maddali K, Pommier Y. Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria. Proc Natl Acad Sci U S A 2010;107:19790-5.
7. Fam HK, Chowdhury MK, Walton C, Choi K, Boerkoel CF, et al. Expression profile and mitochondrial colocalization of Tdp1 in peripheral human tissues. J Mol Histol 2013;44:481-94.
8. Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SY, et al. TDP1 is critical for the repair of DNA breaks induced by sapacitabine, a nucleoside also targeting ATM- and BRCA-deficient tumors. Mol Cancer Ther 2017;16:2543-51.
9. Alagoz M, Wells OS, El-Khamisy SF. TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy. Nucleic Acids Res 2014;42:3089-103.
10. Huang SY, Murai J, Dalla Rosa I, Dexheimer TS, Naumova A, et al. TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs. Nucleic Acids Res 2013;41:7793-803.
11. Interthal H, Chen HJ, Champoux JJ. Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. J Biol Chem 2005;280:36518-28.
12. Lebedeva NA, Rechkunova NI, El-Khamisy SF, Lavrik OI. Tyrosyl-DNA phosphodiesterase 1 initiates repair of apurinic/apyrimidinic sites. Biochimie 2012;94:1749-53.
13. Lebedeva NA, Rechkunova NI, Ishchenko AA, Saparbaev M, Lavrik OI. The mechanism of human tyrosyl-DNA phosphodiesterase 1 in the cleavage of AP site and its synthetic analogs. DNA Repair (Amst) 2013;12:1037-42.
14. Lebedeva NA, Rechkunova NI, Lavrik OI. AP-site cleavage activity of tyrosyl-DNA phosphodiesterase 1. FEBS Lett 2011;585:683-6.
15. El-Khamisy SF, Hartsuiker E, Caldecott KW. TDP1 facilitates repair of ionizing radiation-induced DNA single-strand breaks. DNA Repair (Amst) 2007;6:1485-95.
16. He X, van Waardenburg RC, Babaoglu K, Price AC, Nitiss KC, et al. Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison. J Mol Biol 2007;372:1070-81.
17. Inamdar KV, Pouliot JJ, Zhou T, Lees-Miller SP, Rasouli-Nia A, et al. Conversion of phosphoglycolate to phosphate termini on 3’ overhangs of DNA double strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1. J Biol Chem 2002;277:27162-8.
18. Zhou T, Akopiants K, Mohapatra S, Lin PS, Valerie K, et al. Tyrosyl-DNA phosphodiesterase and the repair of 3’-phosphoglycolate-terminated DNA double-strand breaks. DNA Repair (Amst) 2009;8:901-11.
19. Zhou T, Lee JW, Tatavarthi H, Lupski JR, Valerie K, et al. Deficiency in 3’-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1). Nucleic Acids Res 2005;33:289-97.
20. Murai J, Huang SY, Das BB, Dexheimer TS, Takeda S, et al. Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells. J Biol Chem 2012;287:12848-57.
21. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72:5588-99.
22. Murai J, Marchand C, Shahane SA, Sun H, Huang R, et al. Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform. DNA Repair (Amst) 2014;21:177-82.
23. Prasad R, Horton JK, Dai DP, Wilson SH. Repair pathway for PARP-1 DNA-protein crosslinks. DNA Repair (Amst) 2019;73:71-7.
24. Barthelmes HU, Habermeyer M, Christensen MO, Mielke C, Interthal H, et al. TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II. J Biol Chem 2004;279:55618-25.
25. Nitiss KC, Malik M, He X, White SW, Nitiss JL. Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage. Proc Natl Acad Sci U S A 2006;103:8953-8.
26. Gajewski S, Comeaux EQ, Jafari N, Bharatham N, Bashford D, et al. Analysis of the active-site mechanism of tyrosyl-DNA phosphodiesterase I: a member of the phospholipase D superfamily. J Mol Biol 2012;415:741-58.
27. Hawkins AJ, Subler MA, Akopiants K, Wiley JL, Taylor SM, et al. In vitro complementation of Tdp1 deficiency indicates a stabilized enzyme-DNA adduct from tyrosyl but not glycolate lesions as a consequence of the SCAN1 mutation. DNA Repair (Amst) 2009;8:654-63.
28. Interthal H, Chen HJ, Kehl-Fie TE, Zotzmann J, Leppard JB, et al. SCAN1 mutant Tdp1 accumulates the enzyme - DNA intermediate and causes camptothecin hypersensitivity. EMBO J 2005;24:2224-33.
29. Takashima H, Boerkoel CF, John J, Saifi GM, Salih MA, et al. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet 2002;32:267-72.
30. Cuya SM, Bjornsti MA, van Waardenburg R. DNA topoisomerase-targeting chemotherapeutics: what’s new? Cancer Chemother Pharmacol 2017;80:1-14.
31. Pouliot JJ, Robertson CA, Nash HA. Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae. Genes Cells 2001;6:677-87.
32. Raymond AC, Rideout MC, Staker B, Hjerrild K, Burgin AB Jr. Analysis of human tyrosyl-DNA phosphodiesterase I catalytic residues. J Mol Biol 2004;338:895-906.
33. Scott P, Al Kindi A, Al Fahdi A, Al Yarubi N, Bruwer Z, et al. Spinocerebellar ataxia with axonal neuropathy type 1 revisited. J Clin Neurosci 2019;67:139-44.
34. Dean RA, Fam HK, An J, Choi K, Shimizu Y, et al. Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays. J Biomol Screen 2014;19:1372-82.
35. Duffy S, Fam HK, Wang YK, Styles EB, Kim JH, et al. Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer. Proc Natl Acad Sci U S A 2016;113:9967-76.
36. Comeaux EQ, Cuya SM, Kojima K, Jafari N, Wanzeck KC, et al. Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an alternative nucleophile that can catalyze substrate cleavage. J Biol Chem 2015;290:6203-14.
37. Cuya SM, Comeaux EQ, Wanzeck K, Yoon KJ, van Waardenburg RC. Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin. Oncotarget 2016;7:86660-74.
38. Hirano R, Interthal H, Huang C, Nakamura T, Deguchi K, et al. Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation? EMBO J 2007;26:4732-43.
39. Katyal S, el-Khamisy SF, Russell HR, Li Y, Ju L, et al. TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo. EMBO J 2007;26:4720-31.
40. Li J, Summerlin M, Nitiss KC, Nitiss JL, Hanakahi LA. TDP1 is required for efficient non-homologous end joining in human cells. DNA Repair (Amst) 2017;60:40-9.
41. El-Khamisy SF, Saifi GM, Weinfeld M, Johansson F, Helleday T, et al. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 2005;434:108-13.
42. Davies DR, Interthal H, Champoux JJ, Hol WG. Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures. J Mol Biol 2002;324:917-32.
43. Davies DR, Interthal H, Champoux JJ, Hol WG. Crystal structure of a transition state mimic for Tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide. Chem Biol 2003;10:139-47.
44. Davies DR, Interthal H, Champoux JJ, Hol WG. Explorations of peptide and oligonucleotide binding sites of tyrosyl-DNA phosphodiesterase using vanadate complexes. J Med Chem 2004;47:829-37.
45. Swarup G, Cohen S, Garbers DL. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem Biophys Res Commun 1982;107:1104-9.
46. Liao Z, Thibaut L, Jobson A, Pommier Y. Inhibition of human tyrosyl-DNA phosphodiesterase by aminoglycoside antibiotics and ribosome inhibitors. Mol Pharmacol 2006;70:366-72.
47. Huang SN, Pommier Y, Marchand C. Tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibitors. Expert Opin Ther Pat 2011;21:1285-92.
48. Huang HC, Liu J, Baglo Y, Rizvi I, Anbil S, et al. Mechanism-informed repurposing of minocycline overcomes resistance to topoisomerase inhibition for peritoneal carcinomatosis. Mol Cancer Ther 2018;17:508-20.
49. Chukwudi CU. rRNA binding sites and the molecular mechanism of action of the tetracyclines. Antimicrob Agents Chemother 2016;60:4433-41.
50. Antony S, Marchand C, Stephen AG, Thibaut L, Agama KK, et al. Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1. Nucleic Acids Res 2007;35:4474-84.
51. Banerjee B, Roy A, Sen N, Majumder HK. A tyrosyl DNA phosphodiesterase 1 from kinetoplastid parasite Leishmania donovani (LdTdp1) capable of removing topo I-DNA covalent complexes. Mol Microbiol 2010;78:119-37.
52. Keil A, Frese-Schaper M, Steiner SK, Korner M, Schmid RA, et al. The Topoisomerase I inhibitor irinotecan and the Tyrosyl-DNA phosphodiesterase 1 inhibitor furamidine synergistically suppress murine lupus nephritis. Arthritis Rheumatol 2015;67:1858-67.
53. Dexheimer TS, Gediya LK, Stephen AG, Weidlich I, Antony S, et al. 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors. J Med Chem 2009;52:7122-31.
54. Marchand C, Lea WA, Jadhav A, Dexheimer TS, Austin CP, et al. Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay. Mol Cancer Ther 2009;8:240-8.
55. Sirivolu VR, Vernekar SK, Marchand C, Naumova A, Chergui A, et al. 5-Arylidenethioxothiazolidinones as inhibitors of tyrosyl-DNA phosphodiesterase I. J Med Chem 2012;55:8671-84.
56. Weidlich IE, Dexheimer T, Marchand C, Antony S, Pommier Y, et al. Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores. Bioorg Med Chem 2010;18:182-9.
57. Gushchina IV, Nilov DK, Zakharenko AL, Lavrik OI, Svedas VK. Structure modeling of human Tyrosyl-DNA phosphodiesterase 1 and screening for its inhibitors. Acta Naturae 2017;9:59-66.
58. Lountos GT, Zhao XZ, Kiselev E, Tropea JE, Needle D, et al. Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening. Nucleic Acids Res 2019;47:10134-50.
59. Das BB, Huang SY, Murai J, Rehman I, Ame JC, et al. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res 2014;42:4435-49.
60. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 2014;13:433-43.
61. Jun JH, Kumar V, Dexheimer TS, Wedlich I, Nicklaus MC, et al. Synthesis, anti-cancer screening and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibition activity of novel piperidinyl sulfamides. Eur J Pharm Sci 2018;111:337-48.
62. Zakharenko A, Khomenko T, Zhukova S, Koval O, Zakharova O, et al. Synthesis and biological evaluation of novel tyrosyl-DNA phosphodiesterase 1 inhibitors with a benzopentathiepine moiety. Bioorg Med Chem 2015;23:2044-52.
63. Khomenko T, Zakharenko A, Odarchenko T, Arabshahi HJ, Sannikova V, et al. New inhibitors of tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 7-hydroxycoumarin and monoterpenoid moieties. Bioorg Med Chem 2016;24:5573-81.
64. Li-Zhulanov NS, Zakharenko AL, Chepanova AA, Patel J, Zafar A, et al. A novel class of Tyrosyl-DNA phosphodiesterase 1 inhibitors that contains the octahydro-2H-chromen-4-ol scaffold. Molecules 2018;23:E2468.
65. Mozhaitsev ES, Zakharenko AL, Suslov EV, Korchagina DV, Zakharova OD, et al. Novel inhibitors of DNA repair enzyme TDP1 combining monoterpenoid and adamantane fragments. Anticancer Agents Med Chem 2019;19:463-72.
66. Zakharova O, Luzina O, Zakharenko A, Sokolov D, Filimonov A, et al. Synthesis and evaluation of aryliden- and hetarylidenfuranone derivatives of usnic acid as highly potent Tdp1 inhibitors. Bioorg Med Chem 2018;26:4470-80.
67. Zakharenko AL, Luzina OA, Sokolov DN, Kaledin VI, Nikolin VP, et al. Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topotesmall es, Cyrillican on in vivo tumor models. Eur J Med Chem 2019;161:581-93.
68. Komarova AO, Drenichev MS, Dyrkheeva NS, Kulikova IV, Oslovsky VE, et al. Novel group of tyrosyl-DNA-phosphodiesterase 1 inhibitors based on disaccharide nucleosides as drug prototypes for anti-cancer therapy. J Enzyme Inhib Med Chem 2018;33:1415-29.
69. Salomatina OV, Popadyuk II, Zakharenko AL, Zakharova OD, Fadeev DS, et al. Novel semisynthetic derivatives of bile acids as effective Tyrosyl-DNA phosphodiesterase 1 inhibitors. Molecules 2018;23:E679.
70. Efremova AS, Zakharenko AL, Shram SI, Kulikova IV, Drenichev MS, et al. Disaccharide pyrimidine nucleosides and their derivatives: a novel group of cell-penetrating inhibitors of poly(ADP-ribose) polymerase 1. Nucleosides Nucleotides Nucleic Acids 2013;32:510-28.
71. Maltseva EA, Rechkunova NI, Sukhanova MV, Lavrik OI. Poly(ADP-ribose) polymerase 1 modulates interaction of the nucleotide excision repair factor XPC-RAD23B with DNA via Poly(ADP-ribosyl)ation. J Biol Chem 2015;290:21811-20.
72. Tian LW, Feng Y, Tran TD, Shimizu Y, Pfeifer T, et al. Tyrosyl-DNA phosphodiesterase I inhibitors from the Australian plant macropteranthes leichhardtii. J Nat Prod 2015;78:1756-60.
73. Tian LW, Feng Y, Tran TD, Shimizu Y, Pfeifer T, et al. Achyrodimer F, a tyrosyl-DNA phosphodiesterase I inhibitor from an Australian fungus of the family Cortinariaceae. Bioorg Med Chem Lett 2017;27:4007-10.
